Performance of amide proton transfer imaging to differentiate true progression from therapy-related changes in gliomas and metastases.

Autor: Essed RA; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, De Boelelaan 1117, 1081HV, Amsterdam, Netherlands., Prysiazhniuk Y; Charles University, The Second Faculty of Medicine, Department of Pathophysiology, Prague, Czech Republic., Wamelink IJ; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, De Boelelaan 1117, 1081HV, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, De Boelelaan 1117, 1081HV, Amsterdam, Netherlands., Azizova A; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, De Boelelaan 1117, 1081HV, Amsterdam, Netherlands.; Cancer Center Amsterdam, Imaging and Biomarkers, De Boelelaan 1117, 1081HV, Amsterdam, Netherlands., Keil VC; Department of Radiology and Nuclear Medicine, Amsterdam University Medical Center, De Boelelaan 1117, 1081HV, Amsterdam, Netherlands. v.c.w.keil@amsterdamumc.nl.; Cancer Center Amsterdam, Imaging and Biomarkers, De Boelelaan 1117, 1081HV, Amsterdam, Netherlands. v.c.w.keil@amsterdamumc.nl.; Amsterdam Neuroscience, Brain Imaging, De Boelelaan 1117, 1081HV, Amsterdam, Netherlands. v.c.w.keil@amsterdamumc.nl.
Jazyk: angličtina
Zdroj: European radiology [Eur Radiol] 2024 Aug 12. Date of Electronic Publication: 2024 Aug 12.
DOI: 10.1007/s00330-024-11004-y
Abstrakt: Objectives: Differentiating true progression or recurrence (TP/TR) from therapy-related changes (TRC) is complex in brain tumours. Amide proton transfer-weighted (APT) imaging is a chemical exchange saturation transfer (CEST) MRI technique that may improve diagnostic accuracy during radiological follow-up. This systematic review and meta-analysis elucidated the level of evidence and details of state-of-the-art imaging for APT-CEST in glioma and brain metastasis surveillance.
Methods: PubMed, EMBASE, Web of Science, and Cochrane Library were systematically searched for original articles about glioma and metastasis patients who received APT-CEST imaging for suspected TP/TR within 2 years after (chemo)radiotherapy completion. Modified Quality Assessment of Diagnostic Accuracy Studies-2 criteria were applied. A meta-analysis was performed to pool results and to compare subgroups.
Results: Fifteen studies were included for a narrative synthesis, twelve of which (500 patients) were deemed sufficiently homogeneous for a meta-analysis. Magnetisation transfer ratio asymmetry performed well in gliomas (sensitivity 0.88 [0.82-0.92], specificity 0.84 [0.72-0.91]) but not in metastases (sensitivity 0.64 [0.38-0.84], specificity 0.56 [0.33-0.77]). APT-CEST combined with conventional/advanced MRI rendered 0.92 [0.86-0.96] and 0.88 [0.72-0.95] in gliomas. Tumour type, TR prevalence, sex, and acquisition protocol were sources of significant inter-study heterogeneity in sensitivity (I 2  = 62.25%; p < 0.01) and specificity (I 2  = 66.31%; p < 0.001).
Conclusion: A growing body of literature suggests that APT-CEST is a promising technique for improving the discrimination of TP/TR from TRC in gliomas, with limited data on metastases.
Clinical Relevance Statement: This meta-analysis identified a utility for APT-CEST imaging regarding the non-invasive discrimination of brain tumour progression from therapy-related changes, providing a critical evaluation of sequence parameters and cut-off values, which can be used to improve response assessment and patient outcome.
Key Points: Therapy-related changes mimicking progression complicate brain tumour treatment. Amide proton imaging improves the non-invasive discrimination of glioma progression from therapy-related changes. Magnetisation transfer ratio asymmetry measurement seems not to have added value in brain metastases.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: